Part of NNVC exceptionalism is the assumption that FDA approval is irrelevant to NNVC's success. While the FDA has no legal jurisdiction outside of the U.S., the fact is that many countries look to the U.S. FDA to see if they should approve a drug.
We should also consider the reality that drug profits are much higher in the U.S. than in many other countries. Many on patent drugs are much cheaper in Canada than they are in the U.S., because Canada's one payer system uses the governments' monopsony power to drive the prices down. And the same is true in many other countries. Those "$100 a share" projections assume U.S. levels of prices and profits.
As Doc S said - the US is vaccine centric - they barely even acknowledge the presence of NNVC in the scheme of things. So, go elsewhere where you are appreciated - Canada, the UK, Africa and China.